Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry - ResearchAndMarkets.com

January 30, 2019

DUBLIN--(BUSINESS WIRE)--Jan 30, 2019--The “Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry” report has been added to ResearchAndMarkets.com’s offering.

The rheumatic disorders market is expected to see good growth over the forecast period, increasing from $58.97 billion in 2017 at a compound annual growth rate (CAGR) of 4.46%.

The US market accounted for approximately 43% of the global market in the baseline year 2017, and this is projected to remain stable over the forecast period.

Global Rheumatic Disorders Drugs Market to 2024 covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

The incidence of many indications within the rheumatic disorders therapy area continues to rise and as the global population ages prevalence will increase which is a key driver of market growth. By way of example, the total population living with OA across the seven major markets is expected to increase from 125.76 million in 2017 to 138.44 million in 2024. Market growth will also be driven by the entry of new products to the market, with two drug classes in particular driving strong market growth.

The rheumatic disorders market is dominated by a number of blockbuster drugs, which target tumor necrosis alpha (TNF-a), a key pro-inflammatory cytokine. However, due to several recent and upcoming patent expiries, this drug class will suffer from biosimilar erosion over the forecast period, resulting in revenue decline and reduced market dominance.

The therapy market is dominated by top pharmaceutical companies with 18 of the top 20 pharma companies having at least one marketed or pipeline rheumatic disorders product. By 2024, the 10 companies generating the most revenue in the rheumatic disorders therapy area are all top 20 pharmaceutical companies.

Forecast projections to 2024 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major drug classes are provided within the report.

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Key Marketed Products

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2024

6 Company Analysis and Positioning

7 Strategic Consolidations

8 Appendix

Companies Mentioned

AbbVie Amgen Astellas AstraZeneca Bristol-Myers Squibb ChemoCentryx Corbus Pharmaceuticals Eli Lilly Gilead Sciences GlaxoSmithKline Johnson & Johnson Novartis Pfizer Roche Selecta Biosciences UCB

For more information about this report visit https://www.researchandmarkets.com/research/8thlx8/global_rheumatic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190130005292/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Musculoskeletal Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/30/2019 04:59 AM/DISC: 01/30/2019 04:59 AM


Update hourly